Compare AHRT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHRT | STTK |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.6M | 528.3M |
| IPO Year | 2013 | 2020 |
| Metric | AHRT | STTK |
|---|---|---|
| Price | $6.48 | $7.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 620.4K | 471.8K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 9.30% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $854.92 | N/A |
| Revenue Next Year | $11.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $0.71 |
| 52 Week High | $6.50 | $8.33 |
| Indicator | AHRT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 52.83 |
| Support Level | $5.93 | $1.85 |
| Resistance Level | N/A | $7.68 |
| Average True Range (ATR) | 0.16 | 0.59 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 98.28 | 50.46 |
AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.